Cook Robert Christopher purchased $56K of FLNA

Cook Robert Christopher (Chief Operating& Legal Officer) purchased 121,575 shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.46 on 2026-11-16.

Original reporting
SEC EDGAR · Cook Robert Christopher
Published Nov 18, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FLNA
Bullish
medium confidence
Mentioned
$FLNA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLNABullishLow
01

Why it matters

A COO/legal officer open-market purchase is typically sentiment-positive, but the disclosed value is modest and lacks any fundamental update (no guidance, trial result, or corporate action).

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to be a standalone driver of price.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it also does not clarify whether the buy was discretionary, tax-related, or part of a broader pattern of insider activity.

Relevance 4/10Novelty 6/10Timing: filed 2026-11-18, transaction dated 2026-11-16

Background

The article is an SEC Form 4 insider transaction disclosure for Filana Therapeutics, Inc. (FLNA).

Company-level read

Ticker impact

$FLNABullishMedium confidence
Context

Insider Form 4 shows COO/legal officer Robert Christopher Cook bought 121,575 shares at $0.4600 on 2026-11-16, totaling about $55.9K.

Expected impact

Likely limited near-term impact, with any effect confined to sentiment and short-term order-flow rather than fundamentals.

Evidence & confidence

This is a primary SEC Form 4 disclosure, but the transaction value (~$55.9K) is relatively small and there is no accompanying guidance, deal, or operational catalyst in the text.

Market effects

No sector read-through is provided; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by compensation/portfolio rebalancing, and the article provides no evidence of a strategic reason beyond the purchase itself.

Key entities

  • FLNA

    Filana Therapeutics, Inc., the company whose insider transaction is disclosed.

  • Robert Christopher Cook

    Chief Operating and Legal Officer who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FLNAMed

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov

$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing